Our Pricing

Weight Loss Injections UK: Clinical Guide & Pricing

Published on: June 03, 2026

Finding weight loss injections UK lowest price options requires comparing licensed pharmacies that offer genuine medications with proper clinical oversight. At Cured Pharmacy, we provide transparent upfront pricing on all MHRA-licensed weight loss treatments, with free consultations completed by UK-registered prescribers in under three minutes.

How Weight Loss Injections Work in Clinical Practice

GLP-1 receptor agonists work by mimicking naturally occurring incretin hormones that regulate appetite and glucose metabolism [1]. These medications slow gastric emptying, enhance satiety signals to the brain, and reduce hunger between meals — creating a physiological environment conducive to sustained weight reduction.

Tirzepatide, the active ingredient in Mounjaro, represents a significant advancement as the first dual GIP/GLP-1 receptor agonist licensed by the MHRA [2]. In the SURMOUNT-1 trial, participants achieved average weight reductions of 20.9% at the 15mg dose over 72 weeks, compared to 2.4% with placebo [2]. Semaglutide-based treatments like Wegovy demonstrated average reductions of 14.9% in the STEP-1 trial over 68 weeks [3].

These medications require subcutaneous injection, typically administered once weekly for tirzepatide and semaglutide, or once daily for liraglutide (Saxenda). All injectable weight loss treatments are prescription-only medicines in the UK and must be initiated following clinical assessment by a registered prescriber.

Comparing Weight Loss Injections UK: Efficacy and Mechanisms

The three main injectable options licensed in the UK differ in their receptor activity, dosing frequency, and clinical trial outcomes. Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors, producing dual-pathway effects that clinical data suggest may result in greater weight reduction compared to single-pathway agents [2].

Wegovy (semaglutide) is a selective GLP-1 receptor agonist administered once weekly via pre-filled pen. The STEP trial programme demonstrated consistent weight loss across diverse patient populations, with most participants maintaining reductions when treatment continued beyond one year [3]. Saxenda (liraglutide) uses the same GLP-1 mechanism but requires daily injection due to its shorter half-life.

Your suitability for each medication depends on your BMI, medical history, concurrent medications, and previous weight management attempts. UK prescribers assess contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease.

Which Injection Achieves Best Results?

Head-to-head trials comparing tirzepatide directly to semaglutide show greater average weight reduction with tirzepatide at equivalent treatment durations [4]. However, individual response varies considerably, and some patients achieve excellent outcomes with any GLP-1 therapy when combined with dietary modifications and increased physical activity. The most effective medication is the one you can tolerate consistently over the long term, as weight regain commonly occurs if treatment is discontinued prematurely.

Pricing Transparency for Weight Loss Injections UK

At Cured Pharmacy, pricing is displayed upfront before you begin your consultation, eliminating unexpected costs at checkout. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures all dispensed medications are genuine UK-licensed products sourced through regulated supply chains.

Pricing reflects the prescribed dose and treatment duration determined by your UK prescriber during clinical assessment. We guarantee competitive UK pricing across our entire weight loss range, with no hidden consultation fees or subscription traps. Patients receive exactly what they've ordered, with full product information leaflets and injection technique guidance included in every delivery.

Many patients find that monthly costs decrease over time as they transition to maintenance doses after the initial titration period. Your prescriber will discuss the complete treatment pathway during your consultation, including expected duration and follow-up requirements.

Understanding Treatment Costs Over Time

Weight loss injection therapy typically involves gradual dose escalation over 16-20 weeks to minimise gastrointestinal side effects. Initial months may use lower doses at reduced cost, with prices increasing as you reach therapeutic maintenance doses. This titration approach, recommended by NICE and the MHRA, improves treatment adherence and reduces discontinuation rates due to adverse effects [5].

Clinical Assessment Process at Cured Pharmacy

Every prescription medicine requires clinical assessment by a UK-registered prescriber before dispensing. Our online consultation takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications to GLP-1 therapy.

Your responses are reviewed by GMC-registered doctors or GPhC-registered prescribers who determine whether treatment is clinically appropriate and, if so, which medication and starting dose best suits your circumstances. If a prescriber identifies any safety concerns, they may request additional information, suggest alternative treatments, or recommend you consult your GP for face-to-face assessment.

This process complies fully with General Pharmaceutical Council standards for remote prescribing and ensures patient safety remains paramount. We never dispense prescription medicines without proper clinical oversight, regardless of how straightforward a request may appear.

Managing Side Effects and Treatment Expectations

Gastrointestinal side effects — particularly nausea, diarrhoea, and constipation — are the most commonly reported adverse reactions with GLP-1 therapies [1][3]. These effects typically emerge during dose escalation and diminish over subsequent weeks as your body adapts to the medication. Eating smaller portions, avoiding high-fat meals, and staying well-hydrated can reduce symptom severity.

More serious but rare adverse effects include pancreatitis, gallbladder disease, and acute kidney injury secondary to severe dehydration. You should seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, reduced urine output, or signs of allergic reaction. Your prescriber will discuss warning signs during your consultation and provide written guidance with your first prescription.

Weight loss occurs gradually over months rather than weeks. Clinical trials show maximal effects typically emerge between 60-72 weeks of continuous treatment [2][3]. Patients who combine medication with structured dietary changes and regular physical activity achieve better long-term outcomes than those relying on pharmacotherapy alone.

When to Contact Your Prescriber

Contact your prescriber if you experience persistent vomiting lasting more than 24 hours, severe abdominal pain, symptoms of pancreatitis, or if side effects significantly impair your quality of life. Dose adjustments or switching to an alternative GLP-1 medication may resolve tolerability issues whilst maintaining therapeutic benefit. Never discontinue treatment abruptly without discussing with a healthcare professional, as this may result in rapid weight regain.

Oral and Non-Injectable Weight Loss Options

Not all patients prefer injectable treatments. Orlistat, available as prescription-strength Xenical or lower-dose Alli and Orlos, works by blocking approximately 30% of dietary fat absorption in the intestine [6]. This mechanism differs entirely from GLP-1 therapies and produces more modest weight reductions — typically 5-10% of initial body weight when combined with a reduced-calorie diet.

Orlistat is particularly suitable for patients who cannot tolerate GLP-1 side effects, have contraindications to injectable therapies, or prefer oral medication. Gastrointestinal effects differ from GLP-1 agents, primarily causing oily stools and faecal urgency if dietary fat intake remains high. Adherence to a low-fat diet minimises these effects significantly.

Wegovy oral tablets (semaglutide in pill form) represent a newer option for patients seeking GLP-1 efficacy without injections. Currently available for pre-order, this formulation requires specific administration instructions — taken on an empty stomach with minimal water, followed by a 30-minute fasting period — to ensure adequate absorption. Clinical trials demonstrate comparable efficacy to injectable semaglutide when dosing instructions are followed precisely [7].

Scientific References

1. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. Sjöström, L., Rissanen, A., Andersen, T., et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet, 352(9123), 167–172. https://doi.org/10.1016/S0140-6736(97)11509-4 [accessed 13 August 2026]
7. Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.